Washington Proposal Would Force Full Side-Effect Lists on TV Drug Ads, Threatening Their Viability

A new regulation hidden in the 2026 Unified Agenda of Regulatory and Deregulatory Actions would compel every prescription-drug TV commercial to present its entire list of side effects. The Food and Drug Administration projects that complying with the rule would cost advertisers more than $100 million each year, making most pharmaceutical firms likely to cease TV advertising. Opponents say the policy would reduce patients’ exposure to information about treatment options, favoring health-care bureaucrats and the three largest pharmacy-benefit managers that control most drug formularies.

They also warn that silencing the most regulated ads could drive patients toward unregulated influencers and supplement promoters. The piece, written by John “CZ” Czwartacki, who lives with multiple sclerosis, argues that the rule harms patients, doctors, local TV stations, and sets a precedent for broader speech restrictions. He suggests strengthening FDA enforcement of misleading ads instead of imposing blanket side-effect disclosures.